Opus Genetics Inherited Retinal Disease Programs Featured at Medical and Industry Conferences in September
Opus Genetics (Nasdaq:IRD), a clinical-stage biopharmaceutical company focused on gene therapies for inherited retinal diseases (IRDs), has announced its participation in four major scientific conferences in September 2025.
Key presentations include a discussion on gene and cell therapies at the Ophthalmology Futures Forum in Paris, one-year results from a Phase I/II study of OPGx-LCA5 at the International Symposium on Retinal Degeneration in Prague, and industry insights at the LSX World Congress in Boston. Dr. Sally Tucker and Dr. Ash Jayagopal will be among the key presenters sharing updates on the company's progress in retinal disease treatments.
Opus Genetics (Nasdaq:IRD), un'azienda biofarmaceutica in fase clinica specializzata in terapie geniche per le malattie retinali ereditarie (IRD), ha annunciato la sua partecipazione a quattro importanti conferenze scientifiche previste per settembre 2025.
Tra gli interventi principali figurano una tavola rotonda sulle terapie geniche e cellulari al Ophthalmology Futures Forum di Parigi, i risultati a un anno dello studio di Fase I/II su OPGx-LCA5 al Simposio Internazionale sulla Degenerazione Retinica a Praga, e un approfondimento sul settore durante il LSX World Congress di Boston. La dottoressa Sally Tucker e il dottor Ash Jayagopal saranno tra i relatori che presenteranno gli aggiornamenti sui progressi dell'azienda nelle terapie per le malattie retiniche.
Opus Genetics (Nasdaq:IRD), una compañía biofarmacéutica en fase clínica centrada en terapias génicas para enfermedades retinianas hereditarias (IRD), ha anunciado su participación en cuatro importantes congresos científicos en septiembre de 2025.
Las presentaciones destacadas incluyen una discusión sobre terapias génicas y celulares en el Ophthalmology Futures Forum en París, los resultados a un año del ensayo Fase I/II de OPGx-LCA5 en el Simposio Internacional sobre Degeneración Retiniana en Praga, y análisis del sector en el LSX World Congress en Boston. La Dra. Sally Tucker y el Dr. Ash Jayagopal estarán entre los ponentes clave que compartirán avances en los tratamientos para enfermedades retinianas.
Opus Genetics (Nasdaq:IRD)는 유전성 망막질환(IRD)을 위한 유전자 치료제에 주력하는 임상 단계 바이오제약사로, 2025년 9월에 열리는 네 건의 주요 과학 학회에 참여한다고 발표했습니다.
주요 발표로는 파리에서 열리는 Ophthalmology Futures Forum의 유전자·세포 치료 논의, 프라하에서 개최되는 국제 망막 퇴행 심포지엄에서의 OPGx-LCA5의 1년차 임상 1/2상 결과, 보스턴의 LSX World Congress에서의 업계 전망 발표 등이 포함됩니다. Sally Tucker 박사와 Ash Jayagopal 박사가 회사의 망막 질환 치료 진전 사항을 공유하는 주요 연사로 참여할 예정입니다.
Opus Genetics (Nasdaq:IRD), une société biopharmaceutique en phase clinique spécialisée dans les thérapies géniques pour les maladies rétiniennes héréditaires (IRD), a annoncé sa participation à quatre grandes conférences scientifiques en septembre 2025.
Parmi les interventions principales figurent une table ronde sur les thérapies géniques et cellulaires au Ophthalmology Futures Forum à Paris, les résultats à un an de l'essai de phase I/II d'OPGx-LCA5 lors du Symposium international sur la dégénérescence rétinienne à Prague, et des perspectives sectorielles au LSX World Congress à Boston. La Dre Sally Tucker et le Dr Ash Jayagopal feront partie des intervenants clés présentant les avancées de la société dans les traitements des maladies rétiniennes.
Opus Genetics (Nasdaq:IRD), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase mit Fokus auf Gentherapien für erbliche Netzhauterkrankungen (IRD), hat seine Teilnahme an vier bedeutenden wissenschaftlichen Konferenzen im September 2025 angekündigt.
Zu den Hauptpräsentationen zählen eine Diskussion über Gen- und Zelltherapien beim Ophthalmology Futures Forum in Paris, die Einjahresergebnisse einer Phase I/II-Studie zu OPGx-LCA5 beim International Symposium on Retinal Degeneration in Prag sowie Brancheneinblicke beim LSX World Congress in Boston. Dr. Sally Tucker und Dr. Ash Jayagopal gehören zu den Hauptreferenten, die über die Fortschritte des Unternehmens bei der Behandlung von Netzhauterkrankungen berichten werden.
- None.
- None.
RESEARCH TRIANGLE PARK, N.C., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq:IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders, today announced that it will present on its IRD gene therapy programs at the following scientific conferences in September 2025.
Presentation Details:
Ophthalmology Futures Forum (Retina Forum)
Title: Gene & Cell Therapies for Rare & Common Retinal Diseases: Hype Vs Progress
- Date/Time: September 3, 2025, 12:20 pm
- Presenter: Sally Tucker, Ph.D., Senior Vice President Clinical Development
- Format: Panel Discussion
- Location: Paris, France
Opus Genetics Corporate Presentation
- Date/Time: September 3, 2025, 5:00 pm
- Presenter: Sally Tucker, Ph.D., Senior Vice President Clinical Development
- Location: Paris, France
RD 2025 - International Symposium on Retinal Degeneration
Title: One-year results from a Phase I/II study of OPGx-LCA5 subretinal gene therapy for the treatment of inherited retinal degeneration due to biallelic mutations in the LCA5 gene
- Date: September 15, 2025
- Presenter: Ash Jayagopal, Ph.D., Chief Scientific & Development Officer
- Location: Prague, Czech Republic
LSX World Congress
Title: The Equation for Maturation: Biotech Requirements to Achieve Scale
- Date/Time: September 17, 2025, 12:40 pm
- Presenter: Ben Yerxa, Ph.D., President
- Format: Panel Discussion
- Location: Boston, MA
About Opus Genetics
Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders. The Company’s pipeline features AAV-based gene therapies targeting inherited retinal diseases including Leber congenital amaurosis (LCA), bestrophinopathy, and retinitis pigmentosa. Its lead gene therapy candidates are OPGx-LCA5, which is in an ongoing Phase 1/2 trial for LCA5-related mutations, and OPGx-BEST1, a gene therapy targeting BEST1-related retinal degeneration. Opus Genetics is also advancing Phentolamine Ophthalmic Solution
Contacts:
Investors
Jenny Kobin
Remy Bernarda
IR Advisory Solutions
ir@opusgtx.com
Media
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com
Source: Opus Genetics, Inc.
FAQ
When will Opus Genetics (IRD) present its Phase I/II study results for OPGx-LCA5?
What conferences will Opus Genetics (IRD) attend in September 2025?
Who are the key presenters from Opus Genetics (IRD) at the September 2025 conferences?
What will Opus Genetics (IRD) present at the Ophthalmology Futures Forum?
